NEXT-ChemX Corporation.

CHMX 4 | $4.5 0% 100

(0.0% 1d) (0.0% 1m) (-55.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-27.54% volume)
Earnings Calendar:
Market Cap: $ 128,460,753

Sec Filling | Patents | n/a employees

(US)

add to watch list Paper trade email alert is off

UpHealth Inc

UPH | $0.3 9.13% 0.0% 350K

Professional, Scientific, and T...

(0.0% 1d) (0.0% 1m) (-83.2% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (3.3% volume)
Earnings Calendar: 2024-02-29
Market Cap: $ 5,332,649
https://www.gigcapital2.com
Sec Filling | Patents | 2 employees

(United States) GigCapital Global is a Private-to-Public Equity investment group, sponsoring and operating Special Purpose Acquisition Companies ('SPAC', also known as Blank-Check companies). Founded in 2017 by Dr. Avi Katz, the GigCapital Group and its sponsored SPACs are led by an affiliated team of technology industry experts, deploying a unique Mentor-Investors™ methodology to partner with exceptional privately-held and U.S. and non-U.S. public technology companies led by dedicated, innovative entrepreneurs. The GigCapital Group companies offer financial, operational and executive mentoring to U.S. and global private, and non-U.S. public companies, in order to accelerate their path from inception and as a privately-held entity into the growth-stage as a publicly traded company in the U.S. The partnership of the GigCapital Group with these companies continues through an organic and roll-up strategy growth post the transition to a public company.

msa acquisitions spac blank check

add to watch list Paper trade email alert is off

BioRestorative Therapies, Inc.

BRTX | $1.32 -1.49% -1.52% 37K

Professional, Scientific, and T...

(0.0% 1d) (-5.0% 1m) (-64.1% 1y) (0.0% 2d) (0.0% 3d) (1.5% 7d) (316.06% volume)
Earnings Calendar:
Market Cap: $ 8,936,293
http://www.biorestorative.com/
Sec Filling | Patents | 5 employees

(US) biorestorative therapies, inc. (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. our two core programs, as described below, relate to the treatment of disc/spine disease and metabolic disorders: • disc/spine program (brtxdisc™): our lead cell therapy candidate, brtx-100, is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow. we intend that the product will be used for the non-surgical treatment of protruding and bulging lumbar discs in patients suffering from chronic lumbar disc disease. the brtx-100 production process involves collecting a patient’s bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. in an outpatient procedure, brtx-100 is to be injected by a physician into the patient’s damaged disc. the treatment is intended for patients whose pain has not been alleviated by non-invas

injection t-cell

add to watch list Paper trade email alert is off

1847 Holdings LLC

EFSH 4 | $2.35 1.66% 78K

Professional, Scientific, and T...

(0.0% 1d) (92.7% 1m) (-96.6% 1y) (0.0% 2d) (0.0% 3d) (8.7% 7d) (-82.03% volume)
Earnings Calendar:
Market Cap: $ 2,151,615

Sec Filling | Patents | 26 employees

1847 holdings llc, through its subsidiaries, provides a range of products and services for agriculture, construction, lawn, and garden industries in north america. it operates through two segments, land management services, and retail and appliances. the land management services segment provides waste disposal and various agricultural services, such as manure spreading, land rolling, bin whipping, cleaning of bulk storage bins and silos, equipment rental, trucking, vacuuming, building erection, various shop, and other services to local agricultural and farming communities; and wholesales agricultural equipment and parts. the retail and appliances segment provides a range of appliance services, including sales, delivery/installation, in-home service and repair, extended warranties, and financing to homeowners, builders, and designers. the company also designs, builds, and installs custom cabinetry primarily for custom and semi-custom builders. 1847 partners llc serves as the manager of

add to watch list Paper trade email alert is off

Day One Biopharmaceuticals Inc

DAWN 4 | $13.85 0.58% 0.58% 610K

Professional, Scientific, and T...

(0.0% 1d) (-0.6% 1m) (8.5% 1y) (0.0% 2d) (0.0% 3d) (-3.9% 7d) (0.54% volume)
Earnings Calendar: 2024-03-04
Market Cap: $ 1,210,173,708
https://dayonebio.com
Sec Filling | Patents | 20 employees

(US) Day One Biopharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genomically defined cancers. Day One was founded to address a critical unmet need: children with cancer are being left behind in a cancer drug development revolution. Its name was inspired by the “The Day One Talk”1 that physicians have with patients and their families about an initial cancer diagnosis and treatment plan. The company aims to re-envision cancer drug development and redefine what’s possible for all people living with cancer—regardless of age—starting from Day One. Day One partners with leading clinical oncologists, families, and scientists to identify, acquire, and develop important emerging cancer treatments. The Company’s lead product candidate, DAY101, is an oral, highly-selective type II pan-RAF kinase inhibitor, and is being evaluated in a pivotal Phase 2 clinical trial (FIREFLY-1) in pediatric, adolescent and young adult patients with recurrent or progressive low-grade glioma (pLGG). The Company’s pipeline also includes the investigational agent pimasertib, a clinical-stage, oral, small molecule found to selectively inhibit mitogen-activated protein kinase kinases 1 and 2 (MEK). Through Day One and its collaborators, cancer drug development comes of age. Day One is based in South San Francisco.

treatment diagnostics cancer

add to watch list Paper trade email alert is off

Pharma-Bio Serv, Inc.

PBSV 4 | $0.858 32.5% 100

Professional, Scientific, and T...

(0.0% 1d) (2.0% 1m) (-8.7% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-69.04% volume)
Earnings Calendar:
Market Cap: $ 19,702,377

Sec Filling | Patents | 220 employees

pharma-bio serv is the life sciences industry leader in regulatory compliance, validation, and other regulated industry support services. founded in february 1993, pharma-bio serv offers technical services, product and process transfers, commissioning, process engineering, and technology transfer, to pharmaceutical, medical devices, consumer, chemical and biotechnology industries in puerto rico, united states, brazil and europe. our diverse team offers an integrated service structure designed to provide complete solutions for our client needs. following this holistic approach, we diversified our services with new divisions to support our clients: a laboratory testing facility in puerto rico and spain, scienzalabs, offering microbiological and analytical testing services; metrologix, provides a full range of calibration program management solutions, including calibration standard management, annual calibration workload balancing, and scheduling and data entry; integratek, providing it/s

add to watch list Paper trade email alert is off

Quoin Pharmaceuticals Ltd - ADR

QNRX | $0.759 2.43% 2.37% 81K

Professional, Scientific, and T...

(0.0% 1d) (-21.5% 1m) (-99.0% 1y) (0.0% 2d) (0.0% 3d) (-8.8% 7d) (-10.31% volume)
Earnings Calendar:
Market Cap: $ 2,797,651
https://cellect.co
Sec Filling | Patents | 2020 employees

(IL) Cellect Biotechnology has developed a breakthrough technology, for the selection of stem cells from any given tissue, that aims to improve a variety of stem cell-based therapies.

ceiling t-cell

add to watch list Paper trade email alert is off

Vera Therapeutics Inc - Class A

VERA | $46.695 -2.66% -2.73% 1.1M

Professional, Scientific, and T...

(0.0% 1d) (12.2% 1m) (629.3% 1y) (0.0% 2d) (0.0% 3d) (11.8% 7d) (-37.96% volume)
Earnings Calendar: 2024-03-26
Market Cap: $ 2,542,637,494

Sec Filling | Patents | 46 employees

trucode gene repair is advancing its novel triplex gene editing platform to potentially cure devastating genetic diseases, with initial focus on sickle cell disease and cystic fibrosis. the elegance of triplex gene editing lies in its ability to harness natural, high-fidelity dna repair mechanisms, and its independence from the requirement for exogenous nucleases and viral vectors.

t-cell

add to watch list Paper trade email alert is off

Vivakor, Inc.

VIVK | $0.909 1.0% 0.99% 65K

Professional, Scientific, and T...

(0.0% 1d) (5.8% 1m) (-19.0% 1y) (0.0% 2d) (0.0% 3d) (11.3% 7d) (-91.19% volume)
Earnings Calendar:
Market Cap: $ 23,834,442

Sec Filling | Patents | 25 employees

vivakor inc is a company based out of 2590 holiday rd ste 100, coralville, iowa, united states.

add to watch list Paper trade email alert is off